These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 27694003)

  • 41. In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis.
    Zhang L; Hu C; Huang Z; Li Z; Zhang Q; He Y
    PLoS One; 2021; 16(4):e0250717. PubMed ID: 33901236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long non-coding RNAs: A view to kill ovarian cancer.
    Zamaraev AV; Volik PI; Sukhikh GT; Kopeina GS; Zhivotovsky B
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188584. PubMed ID: 34157315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion.
    Guo Y; Tian P; Yang C; Liang Z; Li M; Sims M; Lu L; Zhang Z; Li H; Pfeffer LM; Yue J
    Pharm Res; 2015 Mar; 32(3):769-78. PubMed ID: 25823356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.
    Logan M; Hawkins SM
    Clin Sci (Lond); 2015 Feb; 128(3):153-80. PubMed ID: 25294164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. microRNA and the pathogenesis of ovarian cancer--a new horizon for molecular diagnostics and treatment?
    Kuhlmann JD; Rasch J; Wimberger P; Kasimir-Bauer S
    Clin Chem Lab Med; 2012 Jan; 50(4):601-15. PubMed ID: 22505556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MicroRNA aberrations: An emerging field for gallbladder cancer management.
    Chandra V; Kim JJ; Mittal B; Rai R
    World J Gastroenterol; 2016 Feb; 22(5):1787-99. PubMed ID: 26855538
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MiRNA as potential biomarkers and therapeutic targets for gastric cancer.
    Shin VY; Chu KM
    World J Gastroenterol; 2014 Aug; 20(30):10432-9. PubMed ID: 25132759
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER2 puzzle pieces: Non-Coding RNAs as keys to mechanisms, chemoresistance, and clinical outcomes in Ovarian cancer.
    Yang F; Yan L; Ji J; Lou Y; Zhu J
    Pathol Res Pract; 2024 Jun; 258():155335. PubMed ID: 38723327
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer.
    Cheng Z; Guo J; Chen L; Luo N; Yang W; Qu X
    Oncotarget; 2015 Sep; 6(28):25381-9. PubMed ID: 26299803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma.
    Zhang YC; Xu Z; Zhang TF; Wang YL
    World J Gastroenterol; 2015 Sep; 21(34):9853-62. PubMed ID: 26379392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Approaches to the detection of ovarian cancer.
    Høgdall E
    Scand J Clin Lab Invest Suppl; 2016; 245():S49-53. PubMed ID: 27435369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
    Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
    Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Panoutsopoulou K; Avgeris M; Magkou P; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Loverix L; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
    Int J Cancer; 2020 Dec; 147(12):3560-3573. PubMed ID: 32621752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.
    Huang S; Qing C; Huang Z; Zhu Y
    Diagn Pathol; 2016 Jun; 11(1):49. PubMed ID: 27283598
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints.
    Fanale D; Corsini LR; Bono M; Randazzo U; Barraco N; Brando C; Cancelliere D; Contino S; Giurintano A; Magrin L; Pedone E; Perez A; Piraino P; Pivetti A; Giovanni ED; Russo TDB; Prestifilippo O; Gennusa V; Pantuso G; Russo A; Bazan V
    Crit Rev Oncol Hematol; 2024 Jan; 193():104220. PubMed ID: 38036154
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.
    Zhang Y; Ling Y; Zhou Y; Shi X; Shen F; Zhou J; Chen Y; Yang F; Gu Y; Wang J
    Cancer Control; 2024; 31():10732748241256819. PubMed ID: 38755968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential role of miR-100 in cancer diagnosis, prognosis, and therapy.
    Qin C; Huang RY; Wang ZX
    Tumour Biol; 2015 Mar; 36(3):1403-9. PubMed ID: 25740059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular mechanisms of microRNAs in regulating epithelial-mesenchymal transitions in human cancers.
    Tang J; Li Y; Wang J; Wen Z; Lai M; Zhang H
    Cancer Lett; 2016 Feb; 371(2):301-13. PubMed ID: 26683775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular mechanisms and clinical implications of miRNAs in drug resistance of esophageal cancer.
    Yang W; Ma J; Zhou W; Zhou X; Cao B; Zhang H; Zhao Q; Fan D; Hong L
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1151-1163. PubMed ID: 28838272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.